标题：CD123靶向治疗母细胞性浆细胞样树突状细胞肿瘤的研究进展与思考

      作者：王莹 1，2 综述 许文婧 2，李转丽 2，杨柯 1，赵霄晨 1，白海 1，2 审校    1.甘肃中医药大学，甘肃 兰州 730000；2.联勤保障部队第940医院血液科，甘肃 兰州 730050

      卷次： 2021年32卷14期

      【摘要】 母细胞性浆细胞样树突状细胞肿瘤(BPDCN)是一种罕见的侵袭性血液系统恶性肿瘤，异质性强，可累及皮肤、淋巴结和骨髓，预后不佳。目前，对BPDCN的治疗尚无统一标准，主要采用急性髓系白血病、急性淋巴细胞白血病和淋巴瘤为主的方案，针对化疗有很高的反应，但中位无事件生存期通常很短，一般不到两年。2018年，SL-401被批准为首个针对2岁及以上BPDCN患者的靶向治疗，靶向治疗的出现为患者的生存提供了希望。本文将重点探讨靶向治疗的优势及最新的思考。
      【关键词】 母细胞性浆细胞样树突状细胞肿瘤；恶性肿瘤；CD123；SL-401；靶向治疗
      【中图分类号】 R730.263 【文献标识码】 A 【文章编号】 1003—6350（2021）14—1865—05

Research progress and consideration of CD123 targeted therapy for blastic plasmacytoid dendritic cell neoplasm.WANG Ying 1,2, XU Wen-jing 2, LI Zhuan-li 2, YANG Ke 1, ZHAO Xiao-chen 1, BAI Hai 1,2.
1. Gansu University of ChineseMedicine, Lanzhou 730000, Gansu, CHINA; 2. Deparment of Hematology, 940 Hospital of PLA Joint Service Support Force,Lanzhou 730050, Gansu, CHINA;【Abstract】 Blastic plasmacytoid dendritic cell tumor (BPDCN) is a rare and invasive hematological malignancywith strong heterogeneity. It may involve the skin, lymph nodes and bone marrow, and has a poor prognosis. At present,there is no unified standard for the treatment of BPDCN, and the main regiments are acute myeloid leukemia, acute lym-phoblastic leukemia and lymphoma. There is a high response to chemotherapy, but the median eventless survival time isusually very short, generally less than two years. In 2018, SL-401 was approved as the first targeted therapy for BPDCNpatients aged 2 years and older, and the emergence of targeted therapy offers hope for patient survival. This article willfocus on the advantages of targeted therapy and the latest thinking.
      【Key words】 Blastic plasmacytoid dendritic cell tumor (BPDCN); Malignant tumor; CD123; SL-401; Targetedtherapy·综述·doi:10.3969/j.issn.1003-6350.2021.14.027基金项目：国家自然科学基金(编号：81372132)；甘肃省自然科学基金(创新基地和人才计划)(编号：20JR5RA602)；甘肃省重大专项项目(编号：1102FKDA005)